Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-1601
- Development stage
- Preclinical
- Lead developer
- Ocumension Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
OT-1601 is an investigational stem cell therapy being developed by Ocumension Therapeutics for the treatment of age-related macular degeneration (AMD) and other retinal pigment epithelium (RPE) diseases. The therapy is designed to repair or replace damaged RPE cells, which are essential for maintaining the health of photoreceptors in the retina. By transplanting stem cell-derived RPE cells, OT-1601 aims to restore the functional integrity of the retinal layer and prevent further vision loss in patients with degenerative ocular conditions. It is currently in early-stage development as part of Ocumension's in-house discovery pipeline.
Beyond the preview
Go deeper on OT-1601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-1601.